ginsenoside-ro and Chemical-and-Drug-Induced-Liver-Injury

ginsenoside-ro has been researched along with Chemical-and-Drug-Induced-Liver-Injury* in 1 studies

Other Studies

1 other study(ies) available for ginsenoside-ro and Chemical-and-Drug-Induced-Liver-Injury

ArticleYear
Chikusetsusaponin V attenuates lipopolysaccharide-induced liver injury in mice.
    Immunopharmacology and immunotoxicology, 2016, Volume: 38, Issue:3

    Chikusetsusaponin V (CsV), a saponin from Panax japonicus, has been reported to inhibit inflammatory responses in lipopolysaccharide (LPS)-induced macrophage cells. However, whether CsV could alleviate LPS-induced liver injury in vivo and the potential mechanisms involved remain unclear. In the present study, we investigated the anti-inflammatory effects of CsV on LPS-induced acute liver injury in mice and further explored the potential mechanisms involved. Our results showed that CsV significantly attenuated elevation of alanine transaminase (ALT) and aspartate aminotransferase (AST) levels and improved liver histopathological changes in LPS-induced mice. In addition, CsV decreased serum tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) levels and inhibited mRNA expressions of inducible nitric oxide synthase (iNOS), TNF-α and IL-1β in LPS challenged mice. Furthermore, CsV inhibited nuclear factor kappa B (NF-κB) activation by downregulating phosphorylated NF-κB, IκB-α, ERK, c-Jun N-terminal kinase (JNK) and p38 levels in the liver tissue, which ultimately decreased nucleus NF-κB protein level. In conclusion, our data suggested that CsV could be a promising drug for preventing LPS challenged liver injury since it attenuated LPS-induced inflammatory responses, partly via inhibiting NF-κB and MAPK signaling pathways.

    Topics: Animals; Chemical and Drug Induced Liver Injury; Interleukin-1beta; Lipopolysaccharides; Male; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Panax; Saponins; Tumor Necrosis Factor-alpha

2016